Podium to Practice: ESMO® 2025 – Lung: Safety Analysis of DeLLphi-304
OR
Explore more from your favourite experts – click their name to access their entire library of content.
Chair
Speakers
Studies / Trials Discussed
LBA100 – Detailed safety analysis of DeLLphi-304: the first phase 3 study to evaluate tarlatamab versus chemotherapy for previously treated small cell lung cancer
Studies/trials discussed:
LBA100 – Detailed safety analysis of DeLLphi-304: the first phase 3 study to evaluate tarlatamab versus chemotherapy for previously treated small cell lung cancer
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.